Rituximab Selectively Suppresses Specific Islet Antibodies

OBJECTIVE: The TrialNet Study Group evaluated rituximab, a B-cell–depleting monoclonal antibody, for its effect in new-onset patients with type 1A diabetes. Rituximab decreased the loss of C-peptide over the first year of follow-up and markedly depleted B lymphocytes for 6 months after administratio...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Yu, Liping, Herold, Kevan, Krause-Steinrauf, Heidi, McGee, Paula L., Bundy, Brian, Pugliese, Alberto, Krischer, Jeff, Eisenbarth, George S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Diabetes Association 2011
Konular:
Immunology and Transplantation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3178300/
https://ncbi.nlm.nih.gov/pubmed/21831969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db11-0674
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller